Related Experiment Video
Updated: Jun 24, 2026
10:34
Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells
Published on: April 14, 2010
Clinical value of blocking IL-6 receptor
Toru Mima1, Norihiro Nishimoto
1Laboratory of Immune Regulation, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Current Opinion in Rheumatology
|April 15, 2009
Summary
Tocilizumab effectively blocks Interleukin-6 receptor (IL-6R) activity, offering a promising treatment for rheumatoid arthritis (RA) and other inflammatory autoimmune diseases. Long-term studies confirm its efficacy and safety in managing these conditions.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Interleukin-6 (IL-6) is a key cytokine in inflammatory and immune responses.
- Overproduction of IL-6 is implicated in autoimmune diseases like rheumatoid arthritis (RA).
- Targeting IL-6 activity presents a therapeutic strategy for these conditions.
Purpose of the Study:
- To review the clinical value of blocking the IL-6 receptor (IL-6R).
- To evaluate tocilizumab, an anti-IL-6R antibody, for treating inflammatory autoimmune diseases.
Main Methods:
- Review of accumulating clinical evidence on tocilizumab efficacy.
- Assessment of tocilizumab in monotherapy and combination treatments.
- Evaluation of long-term safety and efficacy data.
Main Results:
- Tocilizumab demonstrates effectiveness in RA patients, including those unresponsive to other treatments like methotrexate or TNF inhibitors.
- The drug has shown efficacy in slowing structural joint damage progression.
- A 5-year long-term safety and efficacy profile has been established.
- Tocilizumab is also a potential treatment for systemic-onset juvenile idiopathic arthritis, adult-onset Still's disease, and Takayasu arteritis.
Conclusions:
- Blocking IL-6R with tocilizumab is a promising therapeutic approach for RA and other inflammatory conditions.
- Further registry data will be valuable for confirming the long-term safety profile of tocilizumab.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...